Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Retained Earnings: 2010-2025

Historic Retained Earnings for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$467.8 million.

  • Lineage Cell Therapeutics' Retained Earnings fell 16.91% to -$467.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$467.8 million, marking a year-over-year decrease of 16.91%. This contributed to the annual value of -$403.5 million for FY2024, which is 4.84% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Retained Earnings of -$467.8 million as of Q3 2025, which was down 6.80% from -$438.1 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Retained Earnings high stood at -$295.5 million for Q1 2021, and its period low was -$467.8 million during Q3 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Retained Earnings averaged around -$401.0 million, with its median value being -$397.2 million (2024).
  • Data for Lineage Cell Therapeutics' Retained Earnings shows a maximum YoY fell of 16.91% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Retained Earnings stood at -$337.1 million in 2021, then declined by 7.79% to -$363.4 million in 2022, then decreased by 5.91% to -$384.9 million in 2023, then fell by 4.84% to -$403.5 million in 2024, then dropped by 16.91% to -$467.8 million in 2025.
  • Its Retained Earnings was -$467.8 million in Q3 2025, compared to -$438.1 million in Q2 2025 and -$407.6 million in Q1 2025.